Jun 14, 2021 By sarahjibrin HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS® Approach in the Clinic
Oct 26, 2020 By sarahjibrin HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19
Sep 3, 2020 By sarahjibrin KITE AND HIFIBIO THERAPEUTICS PARTNER TO DISCOVER NOVEL TARGETS AND ANTIBODIES AGAINST ACUTE MYELOID LEUKEMIA
Aug 26, 2020 By sarahjibrin HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients
Aug 17, 2020 By sarahjibrin HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19
Aug 28, 2019 By sarahjibrin HiFiBiO Therapeutics Closes $67 Million Series C Financing to Build on Recent Success and Advance Pipeline of Novel Antibody Drugs for Cancer and Autoimmune Disorders
Dec 10, 2018 By sarahjibrin HiFiBiO Therapeutics and Vikas Sukhatme Join Forces to Discover and Develop Novel Antibody Treatments for Cancer
Jul 30, 2018 By Rick Bowen HiFiBiO Therapeutics Signs Multi-Target Antibody Discovery Agreement with Takeda
